ANNOUNCEMENT OF RESULTS

The Company is based in Gerakas, Attica.

The Group is active in the fields of medical consumables and diagnostic centers.

The Group's sales, after the removal of rebates and claw back, amounted to € 18,375 million compared to 18,717 million in the corresponding period last year, decreased by 342 thousand and 1,83%.

The Group's EBIDTA decreased by 7,42% and amounted to €3,410 million compared to €3,683 million in 2023.

Earnings after taxes decreased by 7,56% and amounted to € 1,334 million compared with € 1,443 million in 2023.

The decrease in the above figures is mainly due to the performance of the Group’s subsidiaries (Diagnostic Laboratories) and also to the sale of subsidiary.

Equity increased to 18,569 million from 17,720 million. The Group’s solvency ratio (Net position as % of total assets excluding cash and term deposits) at 31/12/2024 was 80,84%.

The Group’s borrowing amounts to € 8,406 million and relates exclusively to the parent company.

Regarding the financial figures of the parent company MEDICON HELLAS AE, the turnover amounted to € 16,962 million compared with € 16,671 million in the corresponding period last year, an increase of 1,74%.

The company's EBIDTA amounted to € 3,641 million against € 3,169 million in 2023 showing an increase of 14,89%.

Earnings after taxes amounted to € 1,792 million compared with € 1,092 million in 2023. marking an increase.

The increase in sizes for the parent company is due to the increase in turnover, the reduction in operating expenses and the reduction in financial expenses, in relation to the corresponding previous period.